About Aquestive Therapeutics

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies.
Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities.
Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.

website icon
Website
employees icon
Employees
industry icon
Industry
Pharmaceuticals
location icon
Location
30 Technology Drive, Warren, New Jersey 07059, US

Aquestive Therapeutics Alternatives

Industry
Pharmaceuticals
Industry
pharmaceuticals
Industry
Pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals

Frequently Asked Questions about Aquestive Therapeutics

Who is the CEO of Aquestive Therapeutics?

Patricia Lasquinha is the CEO of Aquestive Therapeutics. To contact Patricia Lasquinha email at [email protected] or [email protected].

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more